NPPA seeks clarification on Gilead's drug pricing plea
National Pharmaceutical Pricing Authority has sought clarifications from the company. Gilead had sought exemption from price control for its Tenofovir Alafenamide tablets (brand name Vemlidy) to capture a major chunk of Rs 140-crore market for chronic Hepatitis B in India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 31, 2020 Category: Pharmaceuticals Source Type: news

D/C/F/TAF Tablet Effective Rapid-Initiation HIV Treatment D/C/F/TAF Tablet Effective Rapid-Initiation HIV Treatment
The single-tablet combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is effective for treating newly diagnosed HIV-1 infection before baseline laboratory results are available, according to results from the DIAMOND phase-3 study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 21, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Four-Drug Combination Effective Long-Term for HIV Suppression Four-Drug Combination Effective Long-Term for HIV Suppression
The single-tablet combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is effective for long-term viral suppression in previously untreated patients with HIV-1 infection, according to 96-week results from the AMBER trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 3, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Nigeria: HIV - Experts Urge Increased Awareness On Anti-Retroviral Drug
[Daily Trust] Experts have called for increased enlightenment on the anti- retroviral drug, Tenofovir/Lamivudine/Dolutegravir (TLD). (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - December 30, 2019 Category: Infectious Diseases Source Type: news

Activists and LGBTQ Groups Say These Facebook Ads Spread Dangerous Misinformation About HIV Drugs
Advocacy groups are urging Facebook to remove advertisements that they say unfairly infer that the HIV/AIDS prevention Truvada PrEP (pre-exposure prophylaxis) is dangerous, an allegation they say could endanger the people who are most at risk of contracting the disease. More than 50 HIV/AIDs, LGBTQ and public health advocacy groups released a letter on Monday asking Facebook and Instagram to remove the ads from their platforms. The ads referred specifically to “Truvada PrEP” (the brand name for one of the medications, dtenofovir disoproxil fumarate, used as PrEP) and in some cases more generically to “PrE...
Source: TIME: Health - December 11, 2019 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized health LGBTQ onetime Source Type: news

FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 3, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a pre-exposure prophylaxis (PrEP) indication for Descovy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 4, 2019 Category: Drugs & Pharmacology Source Type: news

FDA OKs Descovy, Second Drug for HIV PrEP FDA OKs Descovy, Second Drug for HIV PrEP
The combo of emtricitabine and tenofovir alafenamide is indicated to reduce the risk for HIV-1 infection from sex (excluding receptive vaginal sex) in at-risk adults and teens weighing at least 35 kg.FDA Approvals (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 3, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Alert Source Type: news

FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic
The U.S. Food and Drug Administration today approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex. (Source: World Pharma News)
Source: World Pharma News - October 3, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Delstrigo (Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 30, 2019 Category: Drugs & Pharmacology Source Type: news

Merck ’s Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed
KENILWORTH, N.J.--(BUSINESS WIRE) September 20, 2019 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) approved supplemental New Drug Applications (sNDAs) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 20, 2019 Category: Drugs & Pharmacology Source Type: news

Weight Gain on INSTI-based HIV Antiretrovirals Weight Gain on INSTI-based HIV Antiretrovirals
Dolutegravir and tenofovir alafenamide can lead to weight gain, especially in women, according to new data that are changing the way researchers look at their study populations.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 26, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Minor Changes in BMD Seen With Tenofovir PrEP in Short Term
WEDNESDAY, July 24, 2019 -- Tenofovir preexposure prophylaxis (PrEP) therapy does not appear to be associated with clinically significant declines in bone mineral density (BMD) in the short term, according to a study published online June 19 in AIDS... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 25, 2019 Category: Pharmaceuticals Source Type: news

Lower than expected risk of bone density decline with Truvada PrEP
(Mary Ann Liebert, Inc./Genetic Engineering News) Researchers have shown that among users of pre-exposure prophylaxis (PrEP) to prevent against AIDS that includes tenofovir (Truvada), those with daily use -- very high adherence -- had only about a 1% average decrease in bone mineral density in the spine and a 0.5% decline in the hip. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 15, 2019 Category: International Medicine & Public Health Source Type: news

Zambia: Govt Gets TAF On HIV
[Times of Zambia] The government has launched a new HIV drug called Tenofovir Alafenamide (TAF) which is said to have fewer side effects on bones and kidney and can suppress viral loads within 10-14 days. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - July 2, 2019 Category: Infectious Diseases Source Type: news

Biktarvy (Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 2, 2019 Category: Drugs & Pharmacology Source Type: news

For the First Time, an Expert Panel Is Recommending a Drug to Prevent High-Risk Groups From Getting HIV
Over the past few decades, doctors and researchers have made admirable progress in controlling the spread of HIV, mainly by using anti-HIV drugs in powerful combinations that can make it harder for the virus to infect cells and pump out more copies of itself. But as any infectious-disease expert knows, preventing new infections is equally as important as treating existing cases to contain an epidemic. And in the U.S. each year, nearly 40,000 people are still newly diagnosed with HIV. With its latest recommendation, published in JAMA, the U.S. Preventive Services Task Force (USPSTF) issued its strongest strategy yet for pre...
Source: TIME: Health - June 11, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized HIV hiv prevention Infectious Disease Source Type: news

Bictegravir-Based Regimen Noninferior to Dolutegravir-Based Regimens for HIV Treatment Bictegravir-Based Regimen Noninferior to Dolutegravir-Based Regimens for HIV Treatment
A single-tablet regimen of bictegravir, emtricitabine and tenofovir alafenamide is noninferior to regimens of dolutegravir coformulated with emtricitabine and tenofovir alafenamide or with abacavir and lamivudine for the initial treatment of HIV-1 infection, according to results from two randomized phase 3 trials.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - June 7, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Reanalysis of Tenofovir Study Changes Some Findings Reanalysis of Tenofovir Study Changes Some Findings
A reanalysis of a study comparing outcomes with tenofovir and entecavir for chronic hepatitis B has yielded different results, with some findings no longer statistically significant, researchers from South Korea report.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - May 15, 2019 Category: Transplant Surgery Tags: Infectious Diseases News Source Type: news

Transgender Females Have Lower Tenofovir Diphosphate Concentrations Transgender Females Have Lower Tenofovir Diphosphate Concentrations
Transgender females taking feminizing hormone therapy (FHT) have lower effective rectal tissue concentrations of tenofovir diphosphate active metabolites, compared with cisgender women and men, researchers report.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 13, 2019 Category: Infectious Diseases Tags: Diabetes & Endocrinology News Source Type: news

Zimbabwe: New Combined HIV First Liners Drug Introduced in Zimbabwe
[263Chat] MYLAN together with New Avakash have introduced a new drug called Tenofovir alafenamide (TAF) meant to assist first liners on ARV treatment in Zimbabwe. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 6, 2019 Category: African Health Source Type: news

Hepatitis B virus infection in children and adolescents
This Series paper summarises knowledge on epidemiology, natural history, and treatment, and highlights key differences from infection acquired in adulthood. It discusses treatment options entecavir and tenofovir, recommending conservative approach to treatment initiation. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 25, 2019 Category: Consumer Health News Source Type: news

Temixys (Lamivudine and Tenofovir Disoproxil Fumarate Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 25, 2019 Category: Drugs & Pharmacology Source Type: news

Treatment Switch for Hep B Patients With Renal, Bone Risk Treatment Switch for Hep B Patients With Renal, Bone Risk
A change to a different form of tenofovir might lower the risk for adverse bone and renal effects, new research shows, but concerns about other risks are emerging.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 18, 2019 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Antivirals for Blocking Mother-to-Child Transmission of HBV Antivirals for Blocking Mother-to-Child Transmission of HBV
Is lamivudine as effective as tenofovir disoproxil fumarate for preventing mother-to-child transmission of HBV?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 20, 2019 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Florida Pharmaceutical Products, Inc., Inks Agreement With Qilu To...
Florida Pharmaceutical Products, Inc., will sell, market and distribute Qilu Pharmaceutical Co., Ltd., ANDA for Tenofovir 300mg tablets.(PRWeb March 14, 2019)Read the full story at https://www.prweb.com/releases/florida_pharmaceutical_products_inc_inks_agreement_with_qilu_to_sell_market_and_distribute_tenofovir_300mg_tablets/prweb16141200.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 14, 2019 Category: Pharmaceuticals Source Type: news

Stopping Oral Antiviral Therapy in Chronic Hep B Possible for Some People Stopping Oral Antiviral Therapy in Chronic Hep B Possible for Some People
A new analysis provides insight into what happens after stopping tenofovir disoproxil fumarate (TDF) in chronic hepatitis B patients with persistent viral suppression who took the drug for at least eight years.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 1, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Symtuza (Darunavir, Cobicistat, Emtricitabine, and Tenofovir   Alafenamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 7, 2019 Category: Drugs & Pharmacology Source Type: news

Effect of Hormonal Contraception on Vaginal Tenofovir Effect of Hormonal Contraception on Vaginal Tenofovir
In what ways might contraceptive hormones impact the pharmacokinetics of topically applied tenofovir?JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 25, 2019 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

MTN researchers begin safety study of a 90-day vaginal ring containing tenofovir
(Microbicide Trials Network) A vaginal ring designed to protect women against both HIV and herpes simplex virus type 2 (HSV-2) is being tested in a new study that aims to determine whether its use for three months is safe. The Phase I study, taking place at three U.S. trial sites, is one of two studies evaluating full 90-day use of the ring, which contains an antiretroviral drug called tenofovir, and the first to enroll participants. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 16, 2019 Category: Infectious Diseases Source Type: news

Four-drug Combo Pill for HIV an Option in Chronic Dialysis Patients Four-drug Combo Pill for HIV an Option in Chronic Dialysis Patients
A daily single-tablet regimen of coformulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide, approved in the U.S. and elsewhere for HIV-1-infected patients with mild-to-moderate chronic kidney disease, may also work well in those with end-stage renal disease on chronic hemodialysis, a new study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

EC Clears Two New HIV Drugs (Pifeltro and Delstrigo) EC Clears Two New HIV Drugs (Pifeltro and Delstrigo)
Pifeltro contains doravirine, a new nonnucleoside reverse transcriptase inhibitor, and Delstrigo is a fixed-dose combination of doravirine, lamivudine, and tenofovir disoproxil fumarate.International Approvals (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - December 1, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Alert Source Type: news

Temixys (Lamivudine and Tenofovir Disoproxil Fumarate Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 28, 2018 Category: Drugs & Pharmacology Source Type: news

Complera (Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 15, 2018 Category: Drugs & Pharmacology Source Type: news

Switching to RPV/FTC/TAF From RPV/FTC/TDF or EFV/FTC/TDF Switching to RPV/FTC/TAF From RPV/FTC/TDF or EFV/FTC/TDF
Switching to a coformulated regimen containing tenofovir alafenamide may provide additional bone and renal benefits in HIV patients.HIV Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 7, 2018 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Switching From Tenofovir in HIV Patients With Renal Toxicity Switching From Tenofovir in HIV Patients With Renal Toxicity
Might a treatment switch help reverse the nephrotoxic effects associated with tenofovir use?HIV Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 22, 2018 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Tenofovir Beats Entecavir for Preventing Liver Cancer? Tenofovir Beats Entecavir for Preventing Liver Cancer?
An observational study reports that in patients with hepatitis B, tenofovir significantly lowers the risk for liver cancer compared with entecavir.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Pre-Exposure Prophylaxis Not Tied to Drug Resistance Pre-Exposure Prophylaxis Not Tied to Drug Resistance
HIV-negative men who receive pre-exposure prophylaxis (PrEP) with tenofovir (TDF) and emtricitabine (FTC) do not develop resistance to these drugs, according to new findings from the IPERGAY ANRS trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 21, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

EMA Panel Backs Two New HIV Drugs EMA Panel Backs Two New HIV Drugs
Pifeltro contains doravirine, a new nonnucleoside reverse transcriptase inhibitor, and Delstrigo is a fixed-dose combination of doravirine, lamivudine, and tenofovir disoproxil fumarate.International Approvals (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 21, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Alert Source Type: news

New Single-pill Combo Effective Against HIV-1 New Single-pill Combo Effective Against HIV-1
A new fixed-dose combination of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) is noninferior to fixed-dose efavirenz/emtricitabine/TDF (EFV/FTC/TDF) in treatment-naive adults with HIV-1 infection, according to results from the DRIVE-AHEAD trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2018 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news

Delstrigo (Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 7, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Approves Two New Drugs for HIV FDA Approves Two New Drugs for HIV
Pifeltro contains doravirine, a new non-nucleoside reverse transcriptase inhibitor, and Delstrigo is a fixed-dose combination of doravirine, lamivudine, and tenofovir disoproxil fumarate.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 31, 2018 Category: Consumer Health News Tags: HIV/AIDS News Alert Source Type: news

FDA Approves Merck ’s Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Appropriate Patients
KENILWORTH, N.J.--(BUSINESS WIRE) August 30, 2018 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Delstrigo, a once-daily fixed-dose combination... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 31, 2018 Category: Drugs & Pharmacology Source Type: news

Pharmacokinetics of TAF When Used With Other Antiretrovirals Pharmacokinetics of TAF When Used With Other Antiretrovirals
How might other antiretroviral agents for the treatment of HIV impact the pharmacokinetics of tenofovir alafenamide?JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 16, 2018 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

In Utero Tenofovir Exposure May Not Affect Infant Bones In Utero Tenofovir Exposure May Not Affect Infant Bones
A new pilot study suggests prenatal tenofovir exposure does not have a significant effect on infant bone mineral content (BMC) or bone mineral density (BMD).Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 14, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Transgender Hormonal Therapy Might Interfere with PrEP
(MedPage Today) -- 13% decrease in tenofovir availability; unclear whether it compromises protection (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - July 26, 2018 Category: Endocrinology Source Type: news

Symtuza (Darunavir, Cobicistat, Emtricitabine, and Tenofovir   Alafenamide Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 25, 2018 Category: Drugs & Pharmacology Source Type: news

Access to Treatment for Hepatitis B Virus Infection - Worldwide, 2016
Among persons living with HBV worldwide, approximately 27 million (10.5%) were aware of their infection, including 4.5 million (16.7%) who were on treatment. In 2017, all but two low- and middle-income countries could legally procure generic entecavir or tenofovir, the medicines active against HBV infection. (Source: PHPartners.org)
Source: PHPartners.org - July 19, 2018 Category: International Medicine & Public Health Source Type: news

Zoledronic Acid Superior to ART-switching for Low Bone Density in HIV Zoledronic Acid Superior to ART-switching for Low Bone Density in HIV
Zoledronic acid improves low bone mineral density (BMD) better than switching from tenofovir disoproxil fumarate (TDF) to another antiretroviral drug in adults with HIV, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 18, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA Approves Symtuza (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
TITUSVILLE, N.J, JULY 17, 2018 – The Janssen Pharmaceutical Companies of Johnson& Johnson today announced the U.S. Food and Drug Administration (FDA) has approved Symtuza (darunavir, cobicistat, emtricitabine and tenofovir alafenamide -... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 18, 2018 Category: Drugs & Pharmacology Source Type: news

Fixed-Dose Bictegravir-Emtricitabine-Tenofovir Maintains Virologic Suppression in HIV Fixed-Dose Bictegravir-Emtricitabine-Tenofovir Maintains Virologic Suppression in HIV
Fixed-dose bictegravir-emtricitabine-tenofovir (Biktarvy) maintains virologic suppression in adults with HIV-1 who are switched from dolutegravir-abacavir-lamivudine or from boosted protease inhibitor-based regimens, according to results from two noninferiority trials.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 13, 2018 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news